# T-LYMPHOCYTE HYBRIDS AND LYMPHOBLASTOID VARIANTS

> **NIH NIH R01** · UNIVERSITY OF WISCONSIN-MADISON · 1993 · $322,040

## Abstract

DESCRIPTION:  (Adapted from applicant's abstract): Knowledge of how cells
acquire and display MHC/peptide complexes is basic to understanding of
how normal and abnormal (eg autoimmune) responses work.  One broad goal
of the work described in this application is to identify MHC-encoded
proteins that are needed for production and presentation of the complexes
and to learn about the function of each protein.  Mutant human B cell
lines in which the formation of MHC/peptide complexes is defective will
be isolated and then cloned genes will be transferred into the mutants
in order to identify genes that repair the defects.  Genes that encode
components of a (peptide?) transporter protein and of proteosomes, as
well as a gene that is needed for acquisition of class II/peptide
complexes, will be emphasized. Various assays will be performed in order
to identify the step in antigen processing/presentation that is defective
in each kind of mutant.

Mutants in which peptide complex formation is impaired produce unstable
"empty" class I or class II molecules that lack bound self-peptides.
Stabilization of empty MHC molecules by binding of peptide will be
exploited as an assay to systematically screen for peptides that can bind
to specific MHC molecules.  Mutant cells that bind exogenous peptides
acquire high densities of specific MHC/peptide complexes.  Such cells
will be used as antigen-presenting cells in attempts to stimulate the in
vitro outgrowth of complex-specific T cells from non-immune individuals.
The goal of the peptide-binding and T cell outgrowth experiments is to
expedite ways of using peptides to elicit or suppress specific immune
responses, as desired.

## Key facts

- **NIH application ID:** 3126190
- **Project number:** 2R01AI015486-15
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **SAM.gov UEI:** LCLSJAGTNZQ7
- **Principal Investigator:** ROBERT Ivan DE MARS
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1993
- **Award amount:** $322,040
- **Award type:** 2
- **Project period:** 1978-12-01 → 1997-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3126190

## Citation

> US National Institutes of Health, RePORTER application 3126190, T-LYMPHOCYTE HYBRIDS AND LYMPHOBLASTOID VARIANTS (2R01AI015486-15). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3126190. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*